doi: 10.1177/09603271211021476 84 JoshuaDBKyung-DonKNeilVKHannahEOSamGStacieKTet al
However, NSAIDs may lead to gastrointestinal bleeding and other adverse effects, while DMARDs can cause immune suppression, increasing the risk of infections ( Figure 1 Despite these treatment advancements, many RA patients face significant side effects and limited efficacy from existing therapies, leading to suboptimal treatment outcomes and continued discomfort (40, 41)
Although a recent trial has shown to be beneficial when antiviral treatment is introduced early during the disease before hospitalization than later in the course of the disease, there is an urgent need for early therapies to reduce the risk of disease progression, prevent transmission, and be widely distributed to meet the worldwide demand (Gottlieb et al., 2022
Completed Phase II and III clinical trials have indicated that the agent has a nonoverlapping toxicity profile and synergistic effects with carboplatin, paclitaxel, and anthracycline, has no cross-drug resistance and is well tolerated, with patients mostly reporting fatigue and nausea
